21 Recruiting Studies Using Datopotamab Deruxtecan
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Datopotamab Deruxtecan
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
📍 Research Site — Tucson, Arizona
Triple Negative Breast Neoplasms
View Study & Checklist ➔Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
📍 Research Site — Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
📍 Research Site — Phoenix, Arizona
NSCLC
View Study & Checklist ➔Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Research Site — La Jolla, California
Advanced or Metastatic NSCLC
View Study & Checklist ➔Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
📍 Ironwood Cancer and Research Center — Chandler, Arizona
Metastatic Non Small Cell Lung Cancer
View Study & Checklist ➔Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
📍 Mayo Clinic — Scottsdale, Arizona
Advanced or Metastatic NSCLC
View Study & Checklist ➔First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
📍 University of California, Los Angeles — Los Angeles, California
Hormone Receptor Positive Breast Cancer
View Study & Checklist ➔A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
📍 Research Site — Tucson, Arizona
Non-small Cell Lung Cancer
View Study & Checklist ➔Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
📍 Southern Cancer Center Pc — Daphne, Alabama
Metastatic Non Small Cell Lung Cancer
View Study & Checklist ➔A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Advanced Solid Tumor
View Study & Checklist ➔Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
📍 Research Site — Chandler, Arizona
Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
📍 UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Breast Cancer
View Study & Checklist ➔DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
📍 Miami Baptist Cancer Institute/ — Miami, Florida
Breast Cancer
View Study & Checklist ➔Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
📍 Research Site — Fountain Valley, California
Non-small Cell Lung Cancer
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
📍 University of Alabama — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
📍 Research Site — Tucson, Arizona
Stomatitis
View Study & Checklist ➔A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
📍 Research Site — San Francisco, California
Advanced Solid Tumors That Are MTAP Deficient
View Study & Checklist ➔Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
📍 Research Site — Anchorage, Alaska
Non-Small Cell Lung Cancer
View Study & Checklist ➔Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
📍 Research Site — Los Angeles, California
Endometrial Cancer
View Study & Checklist ➔Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
📍 Research Site — La Jolla, California
Advanced Solid Malignancies
View Study & Checklist ➔